Therapeutic perspectives of angiotensin-(1-7) in the treatment of cardiovascular disease

Open Pharmacology Journal

Volumn 3, Issue 1, 2009, Pages 21-31

  Höcht, Christian ^a   Mayer, Marcos ^a   Taira, Carlos A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme 2; Cardiovascular disease; Mas receptor

Indexed keywords

[1 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 4 (HYDROXYMETHYL) 7 [[(4 METHYLPHENYL)SULFONYL]OXY] 9H XANTHEN 9 ONE]; ANGIOTENSIN; ANGIOTENSIN (1-7); ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; MINERALOCORTICOID ANTAGONIST; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; RECEPTOR PROTEIN; RETINOIC ACID; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED DRUG RELEASE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; LOW DRUG DOSE; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PLASMA HALF LIFE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEINURIA; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

EID: 77953462663     PISSN: None     EISSN: 18741436     Source Type: Journal    
DOI: 10.2174/1874143600903010021     Document Type: Review

References (113)

1. Paul, M.; Mehr, A.P.; Kreutz, R. Physiology of local renin-angiotensin systems. Physiol. Rev., 2006, 86, 747-803.
2. Santos, R.A.; Simoes e Silva, A.C.; Maric, C.; Silva, D.M.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.; Lopes, M.T.; Bader, M.; Mendes, E.P.; Lemos, V.S.; Campagnole-Santos, M.J.; Schultheiss, H.P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA, 2003, 100, 8258-8263.
3. Iusuf, D.; Henning, R.H.; van Gilst, W.H.; Roks, A.J. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur. J. Pharmacol., 2008, 585, 303-312.
4. Kostenis, E.; Milligan, G.; Christopoulos, A.; Sanchez-Ferrer, C.F.; Heringer-Walther, S.; Sexton, P.M.; Gembardt, F.; Kellett, E.; Martini, L.; Vanderheyden, P.; Schultheiss, H.P.; Walther, T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation, 2005, 111, 1806-1813. (Pubitemid 40525146)
5. Höcht, C.; Mayer, M.A.; Taira, C.A. Advances in the Physiology and Pharmacology of Angiotensin. In: Angiotensin Research Progress. Miura, H.; Sasaki, Y.; Eds. Nova Sience Publishers, 2008, Vol.1; pp 147-171,.
6. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem., 2002, 277, 14838-14843. (Pubitemid 34952556)
7. Yamada, K.; Iyer, S.N.; Chappell, M.C.; Ganten, D.; Ferrario, C.M. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension, 1998, 32, 496-502.
8. Rodgers, K.E.; Ellefson, D.D.; Espinoza, T.; Hsu, Y.H.; diZerega, G.S.; Mehrian-Shai, R. Expression of intracellular filament, collagen, and collagenase genes in diabetic and normal skin after injury. Wound Repair Regen., 2006, 14, 298-305.
9. Allred, A.J.; Diz, D.I.; Ferrario, C.M.; Chappell, M.C. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal Physiol., 2000, 279, 841-850.
10. Santos, R.A.; Ferreira, A.J. Angiotensin-(1-7) and the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens., 2007, 16, 122-128.
11. Santos, R.A.; Campagnole-Santos, M.J.; Baracho, N.C.; Fontes, M.A.; Silva, L.C.; Neves, L.A.; Oliveira, D.R.; Caligiorne, S.M.; Rodrigues, A.R.; Gropen Júnior, C.; Carvalho, W.S.; Simoes E.; Silva, A.C.; Khosla, M.C. Characterization of a new antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull., 1994, 35, 293-298.
12. Silva, D.M.; Vianna, H.R.; Cortes, S.F.; Campagnole-Santos, M.J.; Santos, R.A.; Lemos, V.S. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides, 2007, 28, 702-707.
13. Sampaio, W.O.; Souza dos Santos, R.A.; Faria-Silva, R.; da Mata Machado, L.T.; Schiffrin, E.L.; Touyz, R.M. Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension, 2007, 49, 185-192.
14. Tallant, E.A.; Ferrario, C.M.; Gallagher, P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 1560-1566.
15. Ferrario, C.M.; Trask, A.J.; Jessup, J.Á. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 2281-2290.
16. Su, Z.; Zimpelmann, J.; Burns, K.D. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Inter., 2005, 69, 2212-2218.
17. Giani, J.F.; Gironacci, M.M.; Muñoz, M.C.; Peña, C.; Turyn, D.; Dominici, F.P. Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H1154-H1163.
18. Santos, R.A.; Ferreira, A.J.; Pinheiro, S.V.; Sampaio, W.O.; Touyz, R.; Campagnole-Santos, M.J. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin. Investig. Drugs, 2005, 14, 1019-1031.
19. Oudit, G.Y.; Kassiri, Z.; Patel, M.P.; Chappell, M.; Butany, J.; Backx, P.H.; Tsushima, R.G.; Scholey, J.W.; Khokha, R.; Penninger, J.M. Angiotensin II oxidative stress and inflammation mediate the age dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res., 2007, 75, 29-39.
20. Jaiswal, N.; Diz, D.I.; Chappell, M.C.; Khosla, M.C.; Ferrario, C.M. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension, 1992, 19, II49-II55.
21. Jaiswal, N.; Tallant, E.A.; Jaiswal, R.K.; Diz, D.I.; Ferrario, C.M. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J. Pharmacol. Exp. Ther., 1993, 265, 664-673.
22. Muthalif, M.M.; Benter, I.F.; Uddin, M.R.; Harper, J.L.; Malik, K.U. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J. Pharmacol. Exp. Ther. 1998, 284, 388-398.
23. Rowe, B.P.; Saylor, D.L.; Speth, R.C.; Absher, D.R. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul. Pept., 1995, 56, 139-146.
24. Tallant, E.A.; Lu, X.; Weiss, R.B.; Chappell, M.C.; Ferrario, C.M. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension, 1997, 29, 388-393. (Pubitemid 27074073)
25. Höcht, C.; Gironacci, M.M.; Mayer, M.A.; Schuman, M.; Bertera, F.M.; Taira, C.A. Involvement of angiotensin-(1-7) in the hypothalamic hypotensive effect of captopril in sinoaortic denervated rats. Regul. Pept., 2008, 146, 58-66.
26. Lyngsø, C.; Erikstrup, N.; Hansen, J.L. Functional interactions between 7TM receptors in the Renin-Angiotensin System-Dimerization or crosstalk? Mol. Cell Endocrinol., 2008, 284, 1831-1839.
27. Campbell, D.J. The renin-angiotensin and the kallikrein-kinin systems. Int. J. Biochem. Cell Biol., 2003, 35, 784-791.
28. Fraga-Silva, R.A.; Pinheiro, S.V.; Gonçalves, A.C.; Alenina, N.; Bader, M.; Santos, R.A. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol. Med., 2008, 14, 28-35. (Pubitemid 351356883)
29. Kucharewicz, I.; Chabielska, E.; Pawlak, D.; Matys, T.; Rólkowski, R.; Buczko, W. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst., 2000, 1, 268-272.
30. Sasaki, S.; Higashi, Y.; Nakagawa, K.; Matsuura, H.; Kajiyama, G.; Oshima, T. Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension, 2001, 38, 90-94. (Pubitemid 34224777)
31. Haulica, I.; Bild, W.; Mihaila, C.N.; Ionita, T.; Boisteanu, C.P.; Neagu, B. Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. J. Renin Angiotensin Aldosterone Syst., 2003, 4, 124-128. (Pubitemid 36790185)
32. Peiró, C.; Vallejo, S.; Gembardt, F.; Azcutia, V.; Heringer-Walther, S.; Rodríguez-Mañas, L.; Schultheiss, H.P.; Sánchez-Ferrer, C.F.; Walther, T. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J. Hypertens., 2007, 25, 2421-2425. (Pubitemid 350060381)
33. Baracho, N.C.V.; Simões e Silva, A.C.; Khosla, M.C.; Santos, R.A. Effect of selective angiotensin antagonists on the antidiuresis produced by angiotensin-(1-7) in water-loaded rats. Braz. J. Med. Biol. Res., 1998, 31, 1221-1227.
34. Santos, R.A.; Simões e Silva, A.C.; Magaldi, A.J.; Khosla, M.C.; Cesar, K.R.; Passaglio, K.T.; Baracho, N.C. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension, 1996, 27, 875-884.
35. Magaldi, A.J.; Cesar, K.R.; de Araújo, M.; Simões e Silva, A.C.; Santos, R.A. Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch., 2003, 447, 223-230.
36. Santos, R.A.S.; Campagnole-Santos, M.J.; Andrade, S.P. Angiotensin-(1-7): an update. Regul. Pept., 2000, 91, 45-62.
37. Gironacci, M.M. Contribution of angiotensin-(1-7) to the pathophysiology of hypertension. Braz. J. Hypertens., 2005, 12, 147-152
38. Campagnole-Santos, M.J.; Heringer, S.B.; Batista, E.N.; Khosla, M.C.; Santos, R.A. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am. J. Physiol., 1992, 263, R89-R94.
39. Dobruch, J.; Paczwa, P.; Łoń, S.; Khosla, M.C.; Szczepańska-Sadowska, E. Hypotensive function of the brain angiotensin-(1-7) in Sprague Dawley and renin transgenic rats. J. Physiol. Pharmacol., 2003, 54, 371-381.
40. Moriguchi, A.; Tallant, E.A.; Matsumura, K.; Reilly, T.M.; Walton, H.; Ganten, D.; Ferrario, C.M. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension, 1995, 25, 1260-1265.
41. Höcht, C.; Opezzo, J.A.; Gironacci, M.M.; Peña, C.; Taira, C.A. Hypothalamic cardiovascular effects of Ang-(1-7) in spontaneously hypertensive rats. Regul. Pept., 2006, 135, 39-44. (Pubitemid 43816100)
42. Ferrario, C.M.; Chappell, M.C.; Dean, R.H.; Iyer, S.N. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J. Am. Soc. Nephrol., 1998, 9, 1716-1722.
43. Gorelik, G.; Carbini, L.A.; Scicli, A.G. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J. Pharmacol. Exp. Ther., 1998, 286, 403-410. (Pubitemid 28318016)
44. Brosnihan, K.B.; Li, P.; Ferrario, C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension, 1996, 27, 523-528.
45. Castro, C.H.; Santos, R.A.; Ferreira, A.J.; Bader, M.; Alenina, N.; Almeida, A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension, 2005, 46, 937-942.
46. Neves, L.A.; Almeida, A.P.; Khosla, M.C.; Campagnole-Santos, M.J.; Santos, R.A. Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Braz. J. Med. Biol. Res., 1997, 30, 801-809. (Pubitemid 127519600)
47. Ehrlich, J.R.; Hohnloser, S.H.; Nattel, S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J., 2006, 27, 512-518.
48. Ferreira, A.J.; Santos, R.A.; Almeida, A.P. Angiotensin (1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension, 2001, 38, 665-668.
49. De Mello, W.C.; Ferrario, C.M.; Jessup, J.A. Beneficial vs harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J. Renin Angiotensin Aldosterone Syst., 2007, 8, 74-80.
50. Huentelman, M.J.; Grobe, J.L.; Vazquez, J.; Stewart, J.M.; Mecca, A.P.; Katovich, M.J.; Ferrario, C.M.; Raizada, M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2. Exp. Physiol., 2005, 90, 783-790.
51. Díez-Freire, C.; Vázquez, J.; Correa de Adjounian, M.F.; Ferrari, M.F.; Yuan, L.; Silver, X.; Torres, R.; Raizada, M.K. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genom., 2006, 27, 12-19. (Pubitemid 44511821)
52. Grobe, J.L.; Mecca, A.P.; Mao, H.; Katovich, M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in the DOCA-salt model of hypertension. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H2417-H2423.
53. Santos, R.A.; Ferreira, A.J.; Nadu, A.P.; Braga, A.N.; de Almeida, A.P.; Campagnole-Santos, M.J.; Baltatu, O.; Iliescu, R.; Reudelhuber, T.L.; Bader, M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotection effects in rats. Physiol. Genom., 2004, 17, 292-299. (Pubitemid 38924174)
54. Grobe, J.L.; Mecca, A.P.; Lingis, M.; Shenoy, V.; Bolton, T.A.; Machado, J.M.; Speth, R.C.; Raizada, M.K.; Katovich, M.J. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H736-H742. (Pubitemid 46246920)
55. Iwata, M.; Cowling, R.T.; Gurantz, D.; Moore, C.; Zhang, S.; Yuan, J.X.; Greenberg, B.H. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, H2356-H2363.
56. Mercure, C.; Yogi, A.; Callera, G.E.; Aranha, A.B.; Bader, M.; Ferreira, A.J.; Santos, R.A.; Walther, T.; Touyz, R.M.; Reudelhuber, T.L. Angiotensin-(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res., 2008, 103, 1319-1326.
57. Tallant, E.A.; Diz, D.I.; Ferrario, C.M. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension, 1999, 34, 950-957. (Pubitemid 29501329)
58. Tallant, E.A.; Clark, M.A. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension, 2003, 42, 574-579. (Pubitemid 37237356)
59. Rentzsch, B.; Todiras, M.; Iliescu, R.; Popova, E.; Campos, L.A.; Oliveira, M.L.; Baltatu, O.C.; Santos, R.A.; Bader, M. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improve endothelial function. Hypertension, 2008, 52, 967-973.
60. Freeman, E.J.; Chisolm, G.M.; Ferrario, C.M.; Tallant, E.A. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension, 1996, 28, 104-108.
61. Strawn, W.B.; Ferrario, C.M.; Tallant, E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension, 1999, 30, 535-541.
62. Rodgers, K.E.; Oliver, J.; diZerega, G.S. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother. Pharmacol., 2006, 57, 559-568.
63. Widdop, R.E.; Sampey, D.B.; Jarrott, B. Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension, 1999, 34, 964-968. (Pubitemid 29501331)
64. Benter, I.F.; Yousif, M.H.; Anim, J.T.; Cojocel, C.; Diz, D.I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H684-H691.
65. Iyer, S.N.; Averill, D.B.; Chappell, M.C.; Yamada, K.; Allred, A.J.; Ferrario, C.M. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension, 2000, 36, 417-422. (Pubitemid 30694799)
66. Ferrario, C.M.; Martell, N.; Yunis, C.; Flack, J.M.; Chappell, M.C.; Brosnihan, K.B.; Dean, R.H.; Fernandez, A.; Novikov, S.V.; Pinillas, C.; Luque, M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am. J. Hypertens., 1998, 11, 137-146. (Pubitemid 28137604)
67. Loot, A.E.; Roks, A.J.; Henning, R.H.; Tio, R.A.; Suurmeijer, A.J.; Boomsma, F.; van Gilst, W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 2002, 105, 1548-1550. (Pubitemid 34297630)
68. Katovich, M.J.; Grobe, J.L.; Raizada, M.K. Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr. Hypertens. Rep., 2008, 10, 227-232.
69. Burrell, L.M.; Risvanis, J.; Kubota, E.; Dean, R.G.; MacDonald, P.S.; Lu, S.; Tikellis, C.; Grant, S.L.; Lew, R.A.; Smith, A.I.; Cooper, M.E.; Johnston, C.I. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J., 2005, 26, 369-375.
70. Zisman, L.S.; Keller, R.S.; Weaver, B.; Lin, Q.; Speth, R.; Bristow, M.R.; Canver, C.C. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation, 2003, 108, 1707-1712.
71. Benter, I.F.; Yousif, M.H.; Cojocel, C.; Al-Maghrebi, M.; Diz, D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H666-H672.
72. Tikellis, C.; Johnston, C.I.; Forbes, J.M.; Burns, W.C.; Burrell, L.M.; Risvanis, J.; Cooper, M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension, 2003, 41, 392-397. (Pubitemid 36314606)
73. Wysocki, J.; Ye, M.; Soler, M.J.; Gurley, S.B.; Xiao, H.D.; Bernstein, K.E.; Coffman, T.M.; Chen, S.; Batlle, D. ACE and ACE2 activity in diabetic mice. Diabetes, 2006, 55, 2132-2139.
74. Giani, J.F.; Mayer, M.A.; Muñoz, M.C.; Silberman, E.A.; Höcht, C.; Taira, C.A.; Gironacci, M.M.; Turyn, D.; Dominici, F.P. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab., 2009, 296, E262-E271.
75. Gallagher, P.E.; Tallant, E.A. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis, 2004, 25, 2045-2052. (Pubitemid 39534840)
76. Ellefson, D.D.; diZerega, G.S.; Espinoza, T.; Roda, N.; Maldonado, S.; Rodgers, K.E. Synergistic effects on co-administration of Angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother. Pharmacol., 2004, 53, 15-24.
77. Rodgers, K.E.; Espinoza, T.; Felix, J.; Roda, N.; Maldonado, S.; diZerega, G. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast. Reconstr. Surg., 2003, 111, 1195-1206.
78. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; Bao, L.; Zhang, B.; Liu, G.; Wang, Z.; Chappell, M.; Liu, Y.; Zheng, D.; Leibbrandt, A.; Wada, T.; Slutsky, A.S.; Liu, D.; Qin, C.; Jiang, C.; Penninger, J.M. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med., 2005, 11, 875-879. (Pubitemid 41161120)
79. Imai, Y.; Kuba, K.; Penninger, J.M. The discovery of angiotensin- converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol., 2009, 93, 543-548.
80. Lovren, F.; Pan, Y.; Quan, A.; Teoh, H.; Wang, G.; Shukla, P.C.; Levitt, K.S.; Oudit, G.Y.; Al-Omran, M.; Stewart, D.J.; Slutsky, A.S.; Peterson, M.D.; Backx, P.H.; Penninger, J.M.; Verma, S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H1377-H1384.
81. de Lang, A.; Osterhaus, A.D.; Haagmans, B.L. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481.
82. Gallagher, P.E.; Ferrario, C.M.; Tallant, E.A. Regulation of ACE2 in Cardiac Myocytes and Fibroblasts. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H2373-2379.
83. Keidar, S.; Gamliel-Lazarovich, A.; Kaplan, M.; Pavlotzky, E.; Hamoud, S.; Hayek, T.; Karry, R.; Abassi, Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ. Res., 2005, 97, 946-953. (Pubitemid 41552681)
84. Yamamuro, M.; Yoshimura, M.; Nakayama, M.; Abe, K.; Sumida, H.; Sugiyama, S.; Saito, Y.; Nakao, K.; Yasue, H.; Ogawa, H. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ. J., 2008, 72, 1346-1350.
85. Zhong, J.C.; Huang, D.Y.; Yang, Y.M.; Li, Y.F.; Liu, G.F.; Song, X.H.; Du, K. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension, 2004, 44, 907-912. (Pubitemid 39577420)
86. Ji, H.; Menini, S.; Zheng, W.; Pesce, C.; Wu, X.; Sandberg, K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension. Exp. Physiol., 2008, 93, 648-657.
87. Ferrario, C.M.; Jessup, J.; Gallagher, P.E.; Averill, D.B.; Brosnihan, K.B.; Ann Tallant, E.; Smith, R.D.; Chappell, M.C. Effects of renin-angiotensin system blockade on renal angiotensin (1-7) forming enzymes and receptors. Kidney Int., 2005, 68, 2189-2196.
88. Maia, L.G.; Ramos, M.C.; Fernandes, L.; de Carvalho, M.H.; Campagnole-Santos, M.J.; Souza dos Santos, R.A. Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J. Cardiovasc. Pharmacol., 2004, 3, 685-691.
89. Iyer, S.N.; Ferrario, C.M.; Chappell, M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension, 1998, 31, 356-361.
90. Fernandes, L.; Fortes, Z.B.; Casarini, D.E.; Nigro, D.; Tostes, R.C.; Santos, R.A.; de Carvalho, M.H. Role of PGI2 and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1-7) in resistance vessels of SHR. Regul. Pept., 2005, 127, 183-189.
91. Kucharewicz, I.; Pawlak, R.; Matys, T.; Pawlak, D.; Buczko, W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension, 2002, 40, 774-779. (Pubitemid 35278618)
92. Heringer-Walther, S.; Batista, E.N.; Walther, T.; Khosla, M.C.; Santos, R.A.; Campagnole-Santos, M.J. Baroreflex improvement in SHR after ACEinhibition involves angiotensin-(1-7). Hypertension, 2001, 37, 1309-1314.
93. van der Wouden, E.A.; Henning, R.H.; Deelman, L.E.; Roks, A.J.; Boomsma, F.; de Zeeuw, D. Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. J. Renin Angiotensin Aldosterone Syst., 2005, 6, 96-101. (Pubitemid 41699980)
94. Choudhary, R.; Palm-Leis, A.; Scott, R.C. 3rd; Guleria, R.S.; Rachut, E.; Baker, K.M.; Pan, J. All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H633-H644.
95. Ye, M.; Wysocki, J.; William, J.; Soler, M.J.; Cokic, I.; Batlle, D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol., 2006, 17, 3067-3075. (Pubitemid 44707767)
96. Hernández Prada, J.A.; Ferreira, A.J.; Katovich, M.J.; Shenoy, V.; Qi, Y.; Santos, R.A.; Castellano, R.K.; Lampkins, A.J.; Gubala, V.; Ostrov, D.A.; Raizada, M.K. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension, 2008, 51, 1312-1317. (Pubitemid 351555943)
97. Ferreira, A.J.; Raizada, M.K. Are we poised to target ACE2 for the next generation of antihypertensives? J. Mol. Med., 2008, 86, 685-690.
98. Santos, R.A.S.; Frézard, F.; Ferreira, A.J. Angiotensin-(1-7): Blood, Heart, and Blood Vessels. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2005, 3, 383-391
99. Santos, R.A.; Ferreira, A.J. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc. Drug Rev., 2006, 24, 239-246.
100. Wiemer, G.; Dobrucki, L.W.; Louka, F.R.; Malinski, T.; Heitsch, H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension, 2002, 40, 847-852. (Pubitemid 35434905)
101. Pinheiro, S.V.; Simões e Silva, A.C.; Sampaio, W.O.; de Paula, R.D.;, Mendes, E.P.; Bontempo, E.D.; Pesquero, J.B.; Walther, T.; Alenina, N.; Bader, M.; Bleich, M.; Santos, R.A. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension, 2004, 44, 490-496.
102. Faria-Silva, R.; Duarte, F.V.; Santos, R.A.S. Short-term angiotensin-(1-7) receptor Mas stimulation improves endothelial function in normotensive rats. Hypertension, 2005, 46, 948-952.
103. Lemos, V.S.; Silva, D.M.; Walther, T.; Alenina, N.; Bader, M.; Santos, R.A. The endothelium-dependent vasodilator effect of the nonpeptide ANG-(1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J. Cardiovasc. Pharmacol., 2005, 46, 274-279.
104. Ferreira, A.J.; Jacoby, B.A.; Araújo, C.A.; Macedo, F.A.; Silva, G.A.; Almeida, A.P.; Caliari, M.V.; Santos, R.A. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H1113-H1119. (Pubitemid 46246965)
105. Ferreira, A.J.; Oliveira, T.L.; Castro, M.C.; Almeida, A.P.; Castro, C.H.; Caliari, M.V.; Gava, E.; Kitten, G.T.; Santos, R.A. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci., 2007, 81, 916-923.
106. Ebermann, L.; Spillmann, F.; Sidiropoulos, M.; Escher, F.; Heringer-Walther, S.; Schultheiss, H.P.; Tschöpe, C.; Walther, T. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol., 2008, 590, 276-280.
107. Warner, F.J.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell Mol. Life Sci., 2004, 61, 2704-2713.
108. Holden, J.E.; Jeong, Y.; Forrest, J.M. The endogenous opioid system and clinical pain management. AACN Clin. Issues, 2005, 16, 291-301.
109. Katsanos, G.S.; Anogianaki, A.; Castellani, M.L.; Ciampoli, C.; De Amicis, D.; Orso, C.; Pollice, R.; Vecchiet, J.; Tetè, S.; Salini, V.; Caraffa, A.; Patruno, A.; Shaik, Y.B.; Kempuraj, D.; Doyle, R.; Antinolfi, P.L.; Cerulli, G.; Conti, C.M.; Fulcheri, M.; Neri, G.; Sabatino, G. Biology of neurotensin: revisited study. Int. J. Immunopathol. Pharmacol., 2008, 21, 255-259.
110. Turner, A.J.; Hiscox, J.A.; Hooper, N.M. ACE2: from vasopepti-dase to SARS virus receptor. Trends Pharmacol. Sci., 2004, 25, 291-294. (Pubitemid 38692418)
111. Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A.; Vahanian, A., Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Erdine, S.; Kiowski, W.; Agabiti-Rosei, E.; Ambrosioni, E.; Lindholm, L.H.; Viigimaa, M.; Adamopoulos, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Bertomeu, V.; Clement, D.; Erdine, S.; Farsang, C.; Gaita, D.; Lip, G.; Mallion, J.M.; Manolis, A.J.; Nilsson, P.M.; O'Brien, E.; Ponikowski, P.; Redon, J.; Ruschitzka, F.; Tamargo, J.; van Zwieten, P.; Waeber, B.; Williams, B.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2007, 25, 1105-1187.
112. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J.J.; Ponikowski, P.; Poole-Wilson, P.A.; Strömberg, A.; van Veldhuisen, D.J.; Atar, D.; Hoes, A.W.; Keren, A.; Mebazaa, A.; Nieminen, M.; Priori, S.G.; Swedberg, K.; ESC Committee for Practice Guidelines, Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J., 2008, 29, 2388-2442.
113. Buczko, W.; Kramkowski, K.; Mogielnicki, A. Are the endothelial mechanisms of ACE-Is already established? Pharmacol. Rep., 2006, 58(Suppl): 126-131.